{{Rsnum
|rsid=4734782
|Chromosome=8
|position=104362428
|Orientation=plus
|GMAF=0.4178
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 57.5 | 35.4 | 7.1
| HCB | 29.9 | 45.3 | 24.8
| JPT | 27.4 | 49.6 | 23.0
| YRI | 7.5 | 45.6 | 46.9
| ASW | 8.8 | 49.1 | 42.1
| CHB | 29.9 | 45.3 | 24.8
| CHD | 24.8 | 51.4 | 23.9
| GIH | 40.6 | 45.5 | 13.9
| LWK | 10.1 | 41.3 | 48.6
| MEX | 65.5 | 27.6 | 6.9
| MKK | 12.8 | 44.9 | 42.3
| TSI | 43.1 | 50.0 | 6.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4734782
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109521
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4734782
|overall_frequency_n=67
|overall_frequency_d=126
|overall_frequency=0.531746
|n_genomes=38
|n_genomes_annotated=0
|n_haplomes=57
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}